JP6974167B2 - 線維症治療剤 - Google Patents

線維症治療剤 Download PDF

Info

Publication number
JP6974167B2
JP6974167B2 JP2017525457A JP2017525457A JP6974167B2 JP 6974167 B2 JP6974167 B2 JP 6974167B2 JP 2017525457 A JP2017525457 A JP 2017525457A JP 2017525457 A JP2017525457 A JP 2017525457A JP 6974167 B2 JP6974167 B2 JP 6974167B2
Authority
JP
Japan
Prior art keywords
fibrosis
amino
present
acid
interstitial pneumonia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017525457A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2016208744A1 (ja
Inventor
秋生 藤岡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of JPWO2016208744A1 publication Critical patent/JPWO2016208744A1/ja
Priority to JP2021180108A priority Critical patent/JP7258985B2/ja
Application granted granted Critical
Publication of JP6974167B2 publication Critical patent/JP6974167B2/ja
Priority to JP2023061284A priority patent/JP7498827B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017525457A 2015-06-25 2016-06-24 線維症治療剤 Active JP6974167B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021180108A JP7258985B2 (ja) 2015-06-25 2021-11-04 線維症治療剤
JP2023061284A JP7498827B2 (ja) 2015-06-25 2023-04-05 線維症治療剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015127788 2015-06-25
JP2015127788 2015-06-25
PCT/JP2016/068902 WO2016208744A1 (ja) 2015-06-25 2016-06-24 線維症治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021180108A Division JP7258985B2 (ja) 2015-06-25 2021-11-04 線維症治療剤

Publications (2)

Publication Number Publication Date
JPWO2016208744A1 JPWO2016208744A1 (ja) 2018-04-12
JP6974167B2 true JP6974167B2 (ja) 2021-12-01

Family

ID=57585165

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017525457A Active JP6974167B2 (ja) 2015-06-25 2016-06-24 線維症治療剤
JP2021180108A Active JP7258985B2 (ja) 2015-06-25 2021-11-04 線維症治療剤
JP2023061284A Active JP7498827B2 (ja) 2015-06-25 2023-04-05 線維症治療剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021180108A Active JP7258985B2 (ja) 2015-06-25 2021-11-04 線維症治療剤
JP2023061284A Active JP7498827B2 (ja) 2015-06-25 2023-04-05 線維症治療剤

Country Status (20)

Country Link
US (4) US10449189B2 (enExample)
EP (2) EP3315131B1 (enExample)
JP (3) JP6974167B2 (enExample)
KR (1) KR102647942B1 (enExample)
CN (2) CN107708697B (enExample)
AU (1) AU2016284531B2 (enExample)
BR (1) BR112017028137B1 (enExample)
CA (1) CA2990791A1 (enExample)
DK (1) DK3315131T3 (enExample)
ES (1) ES2928684T3 (enExample)
HU (1) HUE060732T2 (enExample)
MA (1) MA42266A (enExample)
MX (2) MX381792B (enExample)
MY (1) MY191219A (enExample)
PH (1) PH12017502322B1 (enExample)
PL (1) PL3315131T3 (enExample)
PT (1) PT3315131T (enExample)
RU (1) RU2729630C2 (enExample)
SG (2) SG10201912684TA (enExample)
WO (1) WO2016208744A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139608A1 (en) 2006-03-14 2007-12-06 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
US12152246B2 (en) 2006-03-14 2024-11-26 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
BR112017028137B1 (pt) * 2015-06-25 2023-04-04 Taiho Pharmaceutical Co., Ltd Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste
DK3583943T3 (da) 2017-02-15 2024-10-14 Taiho Pharmaceutical Co Ltd Farmaceutisk sammensætning
EP3682882A4 (en) 2017-09-08 2021-06-02 Taiho Pharmaceutical Co., Ltd. ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER
KR20210060465A (ko) 2018-09-18 2021-05-26 다이호야쿠힌고교 가부시키가이샤 아실티오우레아 화합물과 아비라테론의 병용 요법
TWI872203B (zh) * 2020-02-14 2025-02-11 日商大鵬藥品工業股份有限公司 醯基硫脲化合物的製造方法
CN115177636A (zh) * 2022-07-18 2022-10-14 陕西科美致尚生物科技有限公司 一种用于治疗前列腺钙化的组合物及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4094814B2 (ja) 1998-04-28 2008-06-04 敏一 中村 血管新生抑制剤
JP2003238592A (ja) * 2001-12-13 2003-08-27 Japan Tobacco Inc 組織及び血管の再生のための医薬及びその方法
EP1896461A2 (en) 2005-06-30 2008-03-12 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
ZA200804681B (en) * 2005-11-30 2009-11-25 Vertex Pharma Inc Inhibitors of C-Met and uses thereof
US7728017B2 (en) * 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EP2215085B1 (en) * 2007-10-25 2011-09-07 AstraZeneca AB Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
JP4667537B2 (ja) 2008-04-10 2011-04-13 大鵬薬品工業株式会社 アシルチオウレア化合物又はその塩、及びその用途
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
MX2012008898A (es) * 2010-02-03 2012-11-06 Incyte Corp Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
RU2494470C1 (ru) * 2012-04-04 2013-09-27 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") Способ лечения фиброза легких
US9149471B2 (en) 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis
BR112017028137B1 (pt) * 2015-06-25 2023-04-04 Taiho Pharmaceutical Co., Ltd Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste

Also Published As

Publication number Publication date
US20220047572A1 (en) 2022-02-17
JPWO2016208744A1 (ja) 2018-04-12
KR20180021682A (ko) 2018-03-05
SG10201912684TA (en) 2020-03-30
KR102647942B1 (ko) 2024-03-14
AU2016284531A1 (en) 2017-11-30
ES2928684T3 (es) 2022-11-21
PH12017502322B1 (en) 2023-08-30
US10449189B2 (en) 2019-10-22
US20200297716A1 (en) 2020-09-24
PT3315131T (pt) 2022-10-26
EP3315131B1 (en) 2022-09-14
EP3315131A1 (en) 2018-05-02
US11191759B2 (en) 2021-12-07
SG11201709260TA (en) 2018-01-30
MX2017016774A (es) 2018-05-14
DK3315131T3 (da) 2022-11-14
US20180289690A1 (en) 2018-10-11
CN112716952A (zh) 2021-04-30
MY191219A (en) 2022-06-09
JP2022009994A (ja) 2022-01-14
RU2017145271A (ru) 2019-07-25
WO2016208744A1 (ja) 2016-12-29
BR112017028137A2 (pt) 2018-08-28
HUE060732T2 (hu) 2023-04-28
MX381792B (es) 2025-03-13
US11690838B2 (en) 2023-07-04
RU2017145271A3 (enExample) 2019-12-02
PH12017502322A1 (en) 2018-06-25
US10695340B2 (en) 2020-06-30
HK1245639A1 (zh) 2018-08-31
MA42266A (fr) 2018-05-02
EP3315131A4 (en) 2019-02-27
MX2020012989A (es) 2021-02-16
JP7498827B2 (ja) 2024-06-12
AU2016284531B2 (en) 2020-06-04
JP7258985B2 (ja) 2023-04-17
EP3973962A1 (en) 2022-03-30
JP2023076632A (ja) 2023-06-01
CN107708697B (zh) 2021-02-09
CN107708697A (zh) 2018-02-16
US20200009128A1 (en) 2020-01-09
BR112017028137B1 (pt) 2023-04-04
RU2729630C2 (ru) 2020-08-11
CA2990791A1 (en) 2016-12-29
PL3315131T3 (pl) 2022-12-12

Similar Documents

Publication Publication Date Title
JP7498827B2 (ja) 線維症治療剤
TWI696462B (zh) 非酒精性脂肪性肝疾病治療劑
JP5302900B2 (ja) 脂肪性肝疾患の治療用医薬組成物
WO2006025378A1 (ja) 高脂血症治療剤
JP2022505033A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
HK40046439A (en) Therapeutic agent for fibrosis
HK1245639B (en) Therapeutic agent for fibrosis
TW201618777A (zh) 脂質異常症治療劑
EP4501326A1 (en) Therapeutic agent for respiratory disease
WO2026107132A1 (en) Inhibitor of z-alpha1-antitrypsin polymerization to treat alpha-1-antitrypsin (a1at) deficiency in specific patient populations
JP2013526499A (ja) キサンチンオキシダーゼ阻害剤およびスタチンの合剤およびその使用
WO2007123126A1 (ja) 慢性心不全における運動耐容能低下の改善剤
HK40073361A (en) Drug for treatment of nonalcoholic fatty liver disease
JPH08157366A (ja) 脳浮腫治療剤
JPWO2005117853A1 (ja) 高脂血症治療剤及び糖尿病治療剤
JP2016515605A (ja) 抗アレルギー活性を有する新規なカルコン誘導体類

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210315

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211104

R150 Certificate of patent or registration of utility model

Ref document number: 6974167

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250